Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
clinical trial data
Biotech
Nektar eczema asset 'checked all of the boxes' in phase 2
The results set rezpeg up to become “a preferred second-line therapy” in atopic dermatitis.
Darren Incorvaia
Feb 10, 2026 10:55am
Roche unveils data behind BTK inhibitor's phase 3 MS win
Feb 9, 2026 7:00am
Racing BMS and J&J, Bayer ties asundexian to 26% stroke decrease
Feb 5, 2026 12:15pm
Skye links CB1-Wegovy combo to 22.3% weight loss after a year
Feb 2, 2026 8:08am
Merck, Moderna sustain 49% melanoma risk reduction at 5 years
Jan 20, 2026 8:50am
Bright Minds anti-seizure candidate shines in phase 2 win
Jan 6, 2026 10:38am